Appeals court upholds patent on Merck's Vytorin

WASHINGTON Thu Feb 7, 2013 12:23pm EST

WASHINGTON Feb 7 (Reuters) - A U.S. appeals court on Thursday ruled that the patent on Merck & Co's cholesterol fighter Zetia and a related drug, Vytorin, was valid.

The U.S. Court of Appeals for the Federal Circuit did not discuss the ruling at length and simply affirmed a decision by a lower court in New Jersey.

The U.S. District Court for the District of New Jersey had ruled in April that the patent on Merck's cholesterol fighter Zetia and on Vytorin was valid and issued an injunction blocking approval of a generic version by Mylan Inc until the patent expires.

FILED UNDER:
Photo

After wave of QE, onus shifts to leaders to boost economy

DAVOS, Switzerland - Central banks have done their best to rescue the world economy by printing money and politicians must now act fast to enact structural reforms and pro-investment policies to boost growth, central bankers said on Saturday.